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Severe graft-versus-host disease is a major barrier for non-T-cell-depleted haploidentical stem cell transplantation. There is no con-sensus on the optimal graft-versus-host disease prophylaxis. This
study compared the two most commonly used graft-versus-host disease
prophylaxis regimens (post-transplant cyclophosphamide-based vs. the
anti-thymocyte globulin-based) in adults with acute myeloid leukemia
reported to the European Society for Blood and Bone Marrow
Transplantation. A total of 308 patients were analyzed; 193 received post-
transplant cyclophosphamide-based regimen and 115 anti-thymocyte
globulin-based regimen as anti-graft-versus-host disease prophylaxis. The
post-transplant cyclophosphamide-based regimen was more likely to be
associated to bone marrow as graft source (60% vs. 40%; P=0.01).
Patients in the post-transplant cyclophosphamide-based regimen group
had significantly less grade 3-4 acute graft-versus-host disease than those
in the anti-thymocyte globulin-based group (5% vs. 12%, respectively;
P=0.01), comparable to chronic graft-versus-host disease. Multivariate
analysis showed that non-relapse mortality was lower in the post-trans-
plant cyclophosphamide-based regimen group [22% vs. 30%, Hazard
ratio (HR) 1.77(95%CI: 1.09-2.86); P=0.02] with no difference in relapse
incidence. Patients receiving post-transplant cyclophosphamide-based
regimen had better graft-versus-host disease-free, relapse-free survival [HR
1.45 (95%CI: 1.04-2.02); P=0.03] and leukemia-free survival [HR 1.48
(95%CI: 1.03-2.12); P=0.03] than those in the anti-thymocyte globulin-
based group. In the multivariate analysis, there was also a trend for a high-
er overall survival [HR 1.43 (95%CI: 0.98-2.09); P=0.06] for post-trans-
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ABSTRACT
Introduction
Allogeneic hematopoietic stem cell transplantation using
a related haploidentical donor is an alternative option for
patients lacking a fully matched sibling or a well matched
unrelated donor.1 However, due to the number of HLA
mismatches, severe graft-versus-host disease (GvHD) is a
major barrier for successful haploidentical stem cell trans-
plantation (Haplo-SCT). T-cell depletion (TCD) has histor-
ically been successfully used to prevent severe lethal
GvHD, but is limited by graft failure, delayed immune
reconstitution, severe infections, and high incidence of
relapse.2,3 Other approaches, such as administration of
additional post-transplant cell-therapies or optimization of
the conditioning regimens helped to partially overcome
these pitfalls, but were often associated with increased
costs and with very experienced centers.4,5 In recent years,
unmanipulated haploidentical transplant with no ex vivo T-
cell depletion emerged as a viable option and has been per-
formed with increasing frequency and success.6-12 Among
the several methods for GvHD prevention, anti-thymocyte
globulin (ATG) or post-transplant high-dose cyclophos-
phamide (PTCY) are the most effective prophylaxis strate-
gies.13 ATG includes a set of polyclonal antibodies directed
against a wide range of immune cell epitopes that have
been previously demonstrated to reduce GvHD incidence
after allogeneic transplantation from both related and unre-
lated donors.14-16 ATG allows  extensive in vivo T-cell deple-
tion and induces tolerance with expansion of regulatory T
cells.17 
More recently, high-dose PTCY (50 mg/kg days +3 and
+4) has been introduced as an effective GvHD prophy-
laxis by Luznik et al.,9 based on the rationale that
cyclophosphamide is non-toxic to hematopoietic stem
cells and can selectively deplete the alloreactive T cells.18
Both approaches have resulted in very low incidence of
GvHD post Haplo-SCT, despite the broad HLA dispari-
ties. Most publications are mostly from single center
studies on various, usually heterogenous, hematologic
diseases.6,8,9,19 However, there is no consensus on the
GvHD prophylaxis regimen in the setting of non-T-cell
depleted Haplo-SCT using bone marrow (BM) or periph-
eral blood stem cells (PBSC). The current study aimed to
compare these two approaches for GvHD prophylaxis in
patients with acute myeloid leukemia (AML) in complete
remission (CR) reported to the European Group for
Blood and Marrow Transplantation (EBMT) registry.
Methods
Study design
We analyzed all adults (age >18 years) with AML in first or sec-
ond CR (CR1 or CR2) at transplant, reported to the ''Promise''
database, who underwent a Haplo-SCT as first allogeneic SCT
between January 2007 and July 2014. Haplo was defined as recip-
ient-donor number of HLA mismatches over 2. For GvHD pro-
phylaxis, patients received PTCY- or ATG-based treatment. For
the purpose of comparison, the PTCY group consisted of PTCY
alone or PTCY plus other agents (Table 1). Similarly, the ATG
group included patients who received ATG with or without other
drugs (Table 1). Patients who were simultaneously treated with
PTCY and ATG were excluded (n=13). A total of 308 patients
were reported from 78 transplant centers, including 193 patients in
the PTCY and 115 in the ATG group. Eight centers contributed 10
or more patients. All patients or legal guardians provided informed
consent for Haplo-SCT according to the Declaration of Helsinki.
The Review Board of the Acute Leukemia Working Group of the
EBMT approved this study. 
Definitions and statistical analysis
The primary end point was leukemia-free survival (LFS).
Secondary end points were acute GvHD (aGvHD) and chronic
GvHD (cGvHD), relapse incidence (RI), non-relapse mortality
(NRM), GvHD-free, relapse-free survival (GRFS)20,21 and overall
survival (OS). Refined GRFS was defined as survival without the
following events: grade 3-4 acute GvHD, severe cGvHD, disease
relapse, or death from any cause after Haplo-SCT. LFS was calcu-
lated until the date of first relapse, death from any cause or the last
follow up for patients alive in CR. Relapse was defined as disease
recurrence and appearance of blasts in the peripheral blood or BM
(>5%) after CR. NRM was defined as death from any cause other
than relapse. Acute GvHD was graded according to the modified
Seattle Glucksberg criteria23 and cGvHD according to the revised
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plant cyclophosphamide-based regimen versus the
anti-thymocyte globulin-based group. Notably,
center experience was also associated with non-
relapse mortality and graft-versus-host disease-free,
relapse-free survival. Haplo-SCT using a post-trans-
plant cyclophosphamide-based regimen can
achieve better leukemia-free survival and graft-ver-
sus-host disease-free, relapse-free survival, lower
incidence of graft-versus-host disease and non-
relapse mortality as compared to anti-thymocyte
globulin-based graft-versus-host disease prophylaxis
in patients with acute myeloid leukemia. 
Table 1. Details of graft-versus-host disease prophylaxis.
GvHD prevention PTCY group ATG group
PTCY 21 0
PTCY+CSA+MMF 119 0
PTCY+TACRO+MMF 53 0
CSA+MTX 0 23
CSA+MMF 0 8
CSA+MMF+MTX 0 8
CSA+MMF+MTX+BASI 0 40
TACRO+MMF 0 5
SIRO+MMF 0 31
Total 193 115 
GvHD: graft-versus-host disease; PTCY: post-transplant cyclophosphamide; ATG:
antithymocyte globulin; CSA: cyclosporine; MMF: mycophenolate mofetil; TACRO:
tacrolimus; MTX: methotrexate; BASI: basiliximab; SIRO: sirolimus.
Seattle criteria.24 The risk stratification of AML at diagnosis was
established according to the National Comprehensive Cancer
Network guideline (v.1.2015). 
Myeloablative conditioning regimen (MAC) was defined as a
regimen containing either total body irradiation (TBI) with a dose
greater than 6 Gray, a total dose of oral busulfan (Bu) greater than
8 mg/kg, or a total dose of intravenous Bu greater than 6.4 mg/kg
or melphalan at doses of 140 mg/m2 or more. In addition, regimens
containing two alkylating agents were considered as MAC. All
other regimens were defined as reduced intensity conditioning
(RIC). Patients received rabbit ATG (FreseniusTM) (75%) or thy-
moglobulin (25%). 
The median dose of ATG was 20 mg/Kg [interquartile range
(IQR) 20-30 mg/Kg] for FreseniusTM and 10 mg/Kg (IQR: 10-10)
for thymoglobulin. 
GRFS, LFS and OS were estimated by the Kaplan-Meier
method. Cumulative incidence (CI) functions were used to esti-
mate aGvHD, cGvHD, RI and NRM. Competing risks were death
for RI, relapse for NRM, relapse or death for aGvHD and cGvHD.
Univariate analyses were carried out using the log-rank test for
GRFS, OS and LFS, and Gray’s test for CI.
For univariate analysis, comparisons were made by using c2 tests
for categorical and Mann-Whitney tests for continuous variables.
Multivariate analyses were performed using the Cox proportional
hazard model. Type of GvHD prophylaxis, disease status, age at
transplant, type of AML, graft source, conditioning and center
experience were included in the final model. The significance level
was fixed at 0.05, and P values were two-sided. Statistical analyses
were performed with the SPSS 19 (SPSS Inc./IBM, Armonk, NY,
USA) and R 3.0.1 (R Development Core Team, Vienna, Austria)
software packages.
Results
Patients' and transplant characteristics
Patients' and transplant characteristics are summarized
in Table 2. One hundred and ninety-three patients
received PTCY- and 115 ATG-based GvHD prophylaxis.
The median age at Haplo-SCT was 49 and 45 years for the
PTCY and ATG groups, respectively (P=0.38). Of the 308
patients, 61% in the PTCY and 63% in the ATG group
were transplanted in CR1 (P=0.71). There was no differ-
ence in the conditioning regimen; this was  MAC in more
than 50% of cases in both groups (P=0.59). Patients receiv-
ing PTCY were more likely to receive BM as the graft
source (60.1% vs. 39.9%; P=0.01), and had shorter follow
up (18 vs. 36 months; P<0.001) (Table 2).
In the PTCY group, the most common combination
(61.7%) was PTCY plus cyclosporine A (CSA) and
mycophenolate mofetil (MMF), whereas it was PTCY plus
tacrolimus and MMF in 27.5% of the patients. In the ATG
group, the GvHD prophylaxis varied from a combination
of 3-5 drugs; the most common (34.8%) regimen was a 5-
drug combination of ATG with CSA and  MMF,
methotrexate (MTX) and  basiliximab (Table 1).
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Table 2. Characteristics of patients and donors.
Variables PTCY group (n=193) ATG group (n=115) P
Follow up (months) Median (range) 18  (2-61) 36 (3-84) <0.001
Patient age (years) Median (range) 49 (18.18-74.93) 46 (18.2-70.59) 0.383
Donor age (years) Median (range) 34.5(13.08-72.14) 34.05(14.11-70.77) 0.799
Female donor to male patient Yes 48 (24.87% ) 38 (33.33% ) 0.110
Secondary AML Yes 32 (16.58% ) 19 (16.52% ) 0.989
Cytogenetics status at Tx Good 14 (7.25% ) 10 (8.7% ) 0.665
Intermediate 56 (29.02% ) 41 (35.65% )
Poor 12 (6.22% ) 7 (6.09% )
NA/failed 79 (40.93% ) 38 (33.04% )
Secondary AML 32 (16.58% ) 19 (16.52% )
Disease status at Tx CR1 118 (61.14% ) 73 (63.48% ) 0.716
CR2 75 (38.86% ) 42 (36.52% )
Karnofsky at Tx ≥80% 170 (95.51% ) 107 (98.17% ) 0.327
Stem cell source BM 116 (60.1% ) 53 (46.09% ) 0.016
PB 77 (39.9% ) 62 (53.91% )
Conditioning MAC 110 (56.99% ) 62 (53.91% ) 0.598
TBF 50 33
RIC 83 (43.01%) 53 (46.09%)
TBF 18 12
Treo+Flu 1 15
Cy+Flu+TBI 19 16
Cy TBI 34 0
CMV D/R neg to neg 18 (9.68% ) 9 (8.04% ) 0.908
pos to neg 10 (5.38% ) 5 (4.46% )
neg to pos 34 (18.28% ) 19 (16.96% )
pos to pos 124 (66.67% ) 79 (70.54% )
PTCY: post-transplant cyclophosphamide; ATG: antithymocyte globulin; AML: acute myeloid leukemia; Tx: transplant; NA, not available; CR1: first complete remission; CR2: sec-
ond complete remission; BM: bone marrow; PB: peripheral blood; MAC: myeloablative conditioning; TBF: thiotepa+busulfan+fludarabine; RIC: reduced intensity conditioning;
Treo: treosulfan; Cy: cyclophosphamide; Flu: fludarabine; TBI: total body irradiation; CMV: cytomegalovirus; neg: negative; pos: positive; D: donor; R: recipient.
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Table 3. Univariate analysis for 2-year outcomes.
2-year outcome RI % NRM % LFS % OS % aGvHD gr III-IV % cGvHD % ext. cGvHD% GRFS %
[95% CI] [95% CI] [95% CI] [95% CI] [95% CI] [95% CI] [95% CI] [95% CI]
PTCY 21.6% 22.4% 56% 58% 4.7% 33.7% 8.6% 50.9%
[15.6-28.3] [16.3-29] [48.2-63.8] [49.9-66.1] [2.3-8.4] [26.4-41.1] [4.9-13.6] [43.2-58.7]
ATG 22.3% 30.5% 47.2% 54.2% 12.5% 28.3% 12.6% 38.9%
[14.7-30.9] [23.7-37.5] [37.5-56.9] [44.4-63.9] [7.1-19.3] [19.8-37.3] [7-19.9] [29.3-48.5]
P 0.97 0.19 0.26 0.37 0.01 0.33 0.26 0.07
age<50 22.8% 25.2% 52% 58.3% 8.7% 36.7% 12.4% 42.3%
[16.1-30.1] [18.5-32.5] [43.6-60.4] [49.9-66.8] [5-13.7] [28.7-44.6] [7.5-18.7] [33.8-50.8]
Age>50 22% [14.9-30] 25.6% [18.8-32.9] 52.4% [43.4-61.5] 55% [45.9-64.1] 6.5% [3.2-11.4] 26% [18.5-34.1] 7.7% [3.9-13.1] 49.9% [41.1-58.8]
P 0.80 0.95 0.93 0.61 0.42 0.10 0.40 0.39
M 21.9% 26.6% 51.5% 57.1% 6% 34.8% 9% 46% 
[15.3-29.2] [19.8-33.9] [43.1-59.9] [48.8-65.4] [3.1-10.4] [27.2-42.6] [5-14.5] [37.6-54.3]
PB 22.9% 24% 53.1% 56.1% 9.6% 27.8% 12% 45.6%
[15.8-30.9] [17.4-31.2] [44-62.1] [46.7-65.4] [5.4-15.3] [19.8-36.3] [6.7-18.8] [36.5-54.7]
P 0.50 0.90 0.62 0.48 0.21 0.14 0.52 0.38 
CR1 21.2% 24.2% 54.6% 59.5% 6.4% 33.3% 11.2% 47.2%
[15.2-27.9] [18-30.9] [46.8-62.4] [51.8-67.3] [3.5-10.5] [26.2-40.6] [6.9-16.8] [39.3-55.1]
CR2 24.5% 27.7% 47.8% 51.7% 9.7% 29.3% 8.4% 43.5%
[16.2-33.8] [21.2-34.5] [37.6-58] [41.3-62] [5.1-16.1] [20.4-38.8] [4.1-14.7] [33.5-53.4]
P 0.69 0.46 0.83 0.52 0.29 0.69 0.86 0.85
Female to male 23.4% 25.3% 51.4% 53.6% 7.2% 32.9% 12.9% 44.6% 
[14.7-33.2] [19.4-31.5] [40.1-62.6] [42-65.3] [2.9-14.1] [22.8-43.3] [6.5-21.6] [33.4-55.7]
Other 22.1% [16.2-28.7] 24.9% [19.1-31.2] 52.9% [45.5-60.3] 58.5% [51.3-65.8] 7.8% [4.7-11.9] 31.6% [24.8-38.6] 9.1% [5.5-13.9] 46.8% [39.3-54.2]
P 0.83 0.83 0.87 0.83 0.84 0.84 0.31 0.89 
Patient CMV neg 24.5% 25.2% 50.3% 60.2% 5% 32.8% 5.5% 50.7%
[10.1-42.3] [12.8-39.6] [32.1-68.5] [43-77.3] [0.9-15] [16.8-49.9] [1-16.5] [32.5-68.9]
Patient CMV pos 22.4% 24.7% 52.9% 56.8% 8.3% 30.4% 10.2% 45.8%
[17.1-28.1] [12.5-39.1] [46.3-59.5] [50.1-63.5] [5.3-12.1] [24.4-36.5] [6.6-14.7] [39.2-52.4]
P 0.57 0.80 0.80 0.63 0.46 0.92 0.35 0.26
Donor CMV neg 32.3% 19.9% 47.8% 52.7% 6.4% 34.3% 9.8% 43.7%
[21-44.1] [11.6-29.8] [35.4-60.2] [40.5-65] [2.4-13.4] [22.7-46.3] [4.2-18.1] [31.5-55.8]
Donor CMV pos 19.2% [13.8-25.3] 27.1% [17.6-37.6] 53.6% [46.4-60.9] 58.3% [51.1-65.6] 8.4% [5.1-12.6] 29.9% [23.5-36.4] 9.5% [5.8-14.2] 46.8% [39.5-54.1]
P 0.03 0.29 0.41 0.58 0.59 0.80 0.99 0.47
Good 9.5% 12.7% 77.8% 81.1% 0 43.1% 14.3% 63.3% 
[1.5-26.9] [2-33.7] [60.4-95.1] [63.9-98.2] - [22-62.7] [3.2-33.1] [42.6-84]
Interm 30.8% 29.6% 39.6% 47.1% 9.5% 24.1% 8.3% 36.9%
[21-41.2] [9.9-52.6] [28.7-50.4] [35.9-58.3] [4.6-16.4] [15.4-33.7] [3.5-15.7] [26.2-47.7]
Poor 24.7% 23.5% 51.8% 55.9% 10.5% 38.4% 11.8% 46.1%
[7.1-47.8] [6.4-46.6] [27.4-76.3] [30.8-81.1] [1.7-29] [14.6-62.1] [1.7-32.5] [21.6-70.5]
NA/failed 17.1% 27.8% 55.1% 57.5% 8.8% 37.6% 13.9% 44.1%
[10.2-25.4] [8.8-50.9] [45-65.3] [47.4-67.6] [4.5-15] [27.8-47.3] [7.7-21.8] [33.8-54.5]
Sec. AML 22.4% 18.6% 58.9% 62.4% 4% 26.5% 4.3% 57.9% 
[11.3-35.9] [4.1-41.2] [44.4-73.4] [47.8-77] [0.7-12.3] [14.3-40.4] [0.8-13.2] [43.6-72.1]
P 0.25 0.45 0.10 0.28 0.41 0.14 0.50 0.2
De novo 22.4% 26.9% 50.7% 55.4% 8.4% 32.9% 11.5% 43.2%
[17-28.4] [21.2-32.8] [43.9-57.5] [48.5-62.3] [5.4-12.2] [26.7-39.2] [7.6-16.3] [36.3-50]
Secondary 22.4% 18.6% 58.9% 62.4% 4% 26.5% 4.3% 57.9%
[11.3-35.9] [13.8-24.1] [44.4-73.4] [47.8-77] [0.7-12.3] [14.3-40.4] [0.8-13.2] [43.6-72.1]
P 0.75 0.27 0.48 0.58 0.27 0.39 0.14 0.18
Nb haplo in 23.6% 30.9% 45.5% 50.4% 4.8% 22.3% 8.3% 43%
Center<10 [16.5-31.4] [23-39.1] [36.5-54.5] [41.5-59.3] [2.1-9.2] [15.1-30.3] [4.1-14.2] [34.1-51.9]
Nb haplo 20.9% 20.7% 58.4% 59.6% 10.2% 40% 12% 48.5%
In center>10 [14.4-28.2] [13.9-28.5] [50.1-66.7] [51.2-68.1] [6.1-15.5] [31.9-47.9] [7.3-18.1] [40-57]
P 0.39 0.06 0.02 0.12 0.08 0.0002 0.20 0.41
y: years; RI: relapse incidence; CI: confidence interval; NRM: non-relapse mortality; LFS: leukemia-free survival; OS: overall survival; aGvHD: acute graft-versus-host-disease; cGvHD: chronic
graft-versus-host-disease; GRFS; GvHD-free, relapse-free survival; PTCY: post-transplant cyclophosphamide; ATG: anti-thymocyte globulin; BM: bone marrow; PB: peripheral blood; CR: com-
plete remission; CMV: cytomegalovirus; interm: intermediate;  NA: not available; sec.: secondary; AML: acute myeloid leukemia; nb: number; haplo: haplo-identical allogeneic stem cell
transplantation; pos: positive; neg: negative; M: male.
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Table 4. Multivariate analysis for outcomes.
P HR CI lower CI upper
LFS ATG vs. PT-Cy 0.03 1.48 1.03 2.12
CR2 vs. CR1 0.53 1.12 0.78 1.61
Age at Tx (per 10 years) 0.20 1.09 0.95 1.25
Secondary AML 0.25 0.74 0.44 1.25
PB vs. BM 0.81 1.04 0.73 1.49
RIC vs.MAC 0.81 0.96 0.66 1.39
Nb haplo done in the center during the period study <0.001 0.97 0.96 0.99
GRFS ATG vs. PT-Cy 0.03 1.45 1.04 2.02
CR2 vs. CR1 0.64 1.08 0.77 1.52
Age at Tx (per 10 years) 0.58 1.04 0.91 1.17
Secondary AML 0.14 0.69 0.41 1.14
PB vs. BM 0.48 1.13 0.81 1.58
RIC vs.MAC 0.86 0.97 0.68 1.38
Nb haplo done in the center during the period study 0.04 0.99 0.97 1.00
OS ATG vs. PT-Cy 0.06 1.43 0.98 2.09
CR2 vs. CR1 0.20 1.27 0.88 1.85
Age at Tx (per 10 years) 0.15 1.11 0.96 1.28
Secondary AML 0.32 0.76 0.44 1.31
PB vs. BM 0.71 1.07 0.74 1.56
RIC vs.MAC 0.72 0.93 0.63 1.38
Nb haplo done in the center during the period study <0.001 0.97 0.95 0.98
RI ATG vs. PT-Cy 0.58 1.17 0.67 2.02
CR2 vs. CR1 0.59 1.16 0.67 1.98
Age at Tx (per 10 years) 0.70 1.04 0.85 1.27
Secondary AML 0.91 0.96 0.46 2.00
PB vs. BM 0.66 1.13 0.66 1.92
RIC vs.MAC 0.68 1.12 0.64 1.96
Nb haplo done in the center during the period study 0.14 0.98 0.96 1.01
NRM ATG vs. PT-Cy 0.02 1.77 1.09 2.86
CR2 vs. CR1 0.73 1.09 0.67 1.76
Age at Tx (per 10 years) 0.18 1.13 0.94 1.36
Secondary AML 0.15 0.58 0.27 1.24
PB vs. BM 0.90 0.97 0.60 1.57
RIC vs.MAC 0.52 0.85 0.51 1.41
Nb haplo done in the center during the period study <0.001 0.96 0.94 0.98
aGVHD II-IV ATG vs. PT-Cy 0.13 1.43 0.90 2.20
CR2 vs. CR1 0.36 1.25 0.78 2.00
Age at Tx (per 10 years) 0.77 1.00 0.98 1.02
Secondary AML 0.51 1.25 0.65 2.38
PB vs. BM 0.53 1.17 0.72 1.88
RIC vs.MAC 0.98 0.99 0.60 1.65
Nb haplo done in the center during the period study 0.94 1.00 0.98 1.02
aGVHD III-IV ATG vs. PT-Cy 0.04 2.42 1.02 5.75
CR2 vs. CR1 0.40 1.44 0.62 3.35
Age at Tx (per 10 years) 0.22 0.82 0.59 1.13
Secondary AML 0.57 0.64 0.14 3.02
PB vs. BM 0.35 1.53 0.62 3.76
RIC vs.MAC 0.97 1.02 0.39 2.67
Nb haplo done in the center during the period study 0.49 1.01 0.98 1.05
cGVHD ATG vs. PT-Cy 0.08 0.67 0.42 1.06
CR2 vs. CR1 0.83 0.95 0.61 1.48
Age at Tx (per 10 years) 0.40 0.93 0.79 1.10
Secondary AML 0.70 0.88 0.44 1.72
PB vs. BM 0.36 0.81 0.51 1.28
RIC vs.MAC 0.51 0.85 0.52 1.38
Nb haplo done in the center during the period study <0.001 1.06 1.04 1.07
extensive GvHD ATG vs. PT-Cy 0.37 1.43 0.65 3.11
CR2 vs. CR1 0.81 0.91 0.41 2.02
Age at Tx (per 10 years) 0.79 1.04 0.78 1.39
Secondary AML 0.10 0.28 0.06 1.28
PB vs. BM 0.31 1.52 0.68 3.39
RIC vs.MAC 0.98 1.01 0.42 2.40
Nb haplo done in the center during the period study 0.18 1.02 0.99 1.05
HR: hazard ratio; CI: confidence interval; LFS: leukemia-free survival; GRFS: GvHD-free, relapse-free survival; OS: overall survival; RI: relapse incidence; NRM: non-relapse mortality;
aGVHD III-IV: grade III-IV acute graft-versus-host-disease; cGvHD: chronic graft-versus-host-disease; ATG: anti-thymocyte globulin; PT-CY: post-transplant cyclophosphamide; CR1:
first complete remission; CR2: second complete remission; Tx: transplantation; AML: acute myeloid leukemia; PB: peripheral blood; BM: bone marrow; RIC: reduced intensity con-
ditioning; MAC: myeloablative conditioning; haplo: hapo-identical stem cell transplantation; Nb: number.
GRFS, LFS and OS 
The GRFS, LFS and OS at two years in the whole popu-
lation were 45.7% (95%CI: 39.5%-51.9%), 52.9%
(95%CI: 45.9%-58.3%) and 56.6% (95%CI: 50.46%-
62.8%), respectively.
GRFS, LFS and OS were 50.9% (95%CI: 43.2%-58.7%)
versus 38.9% (95%CI: 29.3%-48.5%) (P=0.07), 56%
(95%CI: 48.2%-63.8%) versus 47.2% (95%CI: 37.5%-
56.9%) (P=0.26) and 58% (95%CI: 49.9-66.1%) versus
54.2% (95%CI: 44.4%-63.9%) (P=0.37), for patients receiv-
ing PTCY versus ATG, respectively (Table 3 and Figure 1).
According to disease status at Haplo-SCT, the 2-year LFS
was 54.6% (95%CI: 46.8%-62.4%) for patients in CR1 and
47.8% (95%CI: 37.6%-58%) in CR2 (P=0.93). Detailed
results of the univariate analysis are reported in Table 3.  
Multivariate analysis (Table 4) showed a significantly
lower LFS [HR 1.48; (95%CI: 1.03-2.12; P=0.034)], and
GRFS [HR 1.45; (95%CI: 1.04-2.02; P=0.030)] for patients
receiving ATG. In addition, another independent factor
associated with outcomes was the increase in number of
Haplo-SCT performed per year per transplant center (ana-
lyzed as a continuous variable) [LFS (HR 0.97; (95%CI:
0.96-0.99; P<0.001)], and GRFS [HR 0.99; (95%CI: 0.97-
1.00; P<0.04)]. The center effect affected outcomes in both
groups when analyzed separately (data not shown).
Graft-versus-host disease  
The CI of grade 2-4 and grade 3-4 aGvHD at day 100
was 25% (95%CI: 20%-30%) and 7.6% (95%CI: 5%-
11%), respectively.  Grade 2-4 aGvHD was 21% for
patients receiving ATG versus 31% for those with PT-Cy
(P=0.07). Patients receiving PTCY as GvHD prophylaxis
had significantly lower grade 3-4 aGvHD than those
receiving ATG (4.7% vs. 12.5%; P=0.01) (Figure 2A). In the
multivariate analysis (Table 4), the use of ATG was the
only factor associated with occurrence of severe grade 3-4
aGvHD (HR 2.42; 95%CI: 1.20%-5.75%; P=0.04).
The CI of cGvHD and of extensive cGvHD at two years
was 31.8% (95%CI: 26.2%-37.5%) and 10.2% (95%CI:
6.9%-14.4%), respectively. There was no difference in
incidence of cGvHD (Figure 2B) between the two groups
(95%CI: 33.7% vs. 28.3%; P=0.33), and for extensive
cGvHD 8.6% versus 12.6% (P=0.26) for PTCY and ATG,
respectively. In the multivariate analysis (Table 4), experi-
ence of the transplant center (increase in number of Haplo-
SCT per year) was the only factor associated with total
cGvHD (HR 1.06; 95%CI: 1.04-1.07; P<0.001).
Non-relapse mortality and relapse 
The CI of 2-year NRM was 25.4% (95%CI: 20.4%-
30.7%). In the multivariate analysis, the use of ATG as
GvHD prophylaxis was an independent factor for higher
NRM (HR 1.77; 95%CI: 1.09-2.86; P=0.02) (Figure 2C), as
was also the center experience (HR 0.96; 95%CI: 0.94-
0.98; P<0.001). 
The CI of relapse at two years was 22.4% (95%CI:
17.4%-27.8%) in the whole population, and it was com-
parable between the two groups (21.6% vs. 22.3%;
P=0.97) (Figure 2D). No factors were found to be associat-
ed with relapse in the multivariate analysis.
One hundred and twenty-two patients died, 62% of
transplant-related causes and 38% due to disease recur-
rence. Infections and GvHD were the most common caus-
es of NRM. There was no difference in  causes of death
between the two GvHD prophylaxis groups.
Discussion
The aim of our study was to compare the different
GvHD prophylaxis in the non-TCD Haplo-SCT setting. In
a homogenous population of AML in CR, we showed that
the use of PTCY for GvHD prophylaxis was associated
with better LFS and GRFS, similar relapse and cGvHD, less
NRM and less severe aGvHD, than in the ATG group. 
The incidence of grade 3-4 aGvHD in both groups is
consistent with the previous reports in this setting. The
largest study from Huang et al. reported a 10%-14% inci-
dence of severe aGvHD in patients receiving ATG-based
GvHD prophylaxis.6,7  Other groups reported an incidence
of grade 3-4 aGvHD ranging from 9±3% to 22±8% using
the association of ATG with CSA, MTX plus MMF and
A. Ruggeri et al.
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Figure 1. (A). Overall survival (OS), (B) leukemia-free survival (LFS), (C) graft-ver-
sus-host disease (GvHD)-free, relapse-free survival (GRFS) for post-transplant
high-dose cyclophosphamide (PTCY)-based and anti-thymocyte globulin (ATG)-
based GvHD prophylaxis.
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basiliximab8,25 or sirolimus and MMF26 as GvHD prophy-
laxis. 
The PTCY regimen was first introduced by Luznik et
al.9,27 using PTCY with tacrolimus and MMF, BM graft and
RIC conditioning, with a low 5% incidence of grade 3-4
aGvHD. This platform was rapidly adopted by other cen-
ters with similar results. Bacigalupo et al.19 slightly modi-
fied the GvHD prophylaxis with PTCY (50 mg/kg  days
+3,+5) together with CSA and MMF, resulting in a 4%
incidence of grade 3-4 aGvHD.  The above historical data
and the present retrospective study suggest that PTCY has
a stronger effect in preventing severe GvHD. However,
further prospective randomized studies are warranted to
further confirm this conclusion. Despite the lower inci-
dence in severe aGvHD in the PTCY group, we did not
find an advantage in terms of cGvHD or extensive
cGvHD. Notably, ATG has been recently shown to signif-
icantly reduce the incidence of cGvHD after allogeneic
stem cell transplantation from related and unrelated
donors.15,28 
Importantly, in our series, there was no difference in  the
incidence of GvHD  according to the source of stem cell.
The use of BM or PBSC did not impact on the main out-
comes both in the univariate and multivariate analysis.  
The NRM in the PTCY group was lower than in ATG
group. In vivo TCD is a known risk factor associated with
high incidence of infection and NRM, as reported in adult
patients with acute leukemia in the unrelated donor set-
ting.29 Moreover, a very favorable toxicity profile of PTCY
Haplo-SCT has been observed, also in comparison with
CD34+ selected graft and ATG30 and in the unmanipulat-
ed setting,  in older patients.31 Similarly, Kasamon et al.
showed comparable NRM between younger patients and
those over 70 years of age.32 
A major concern related to the PTCY protocol is the
high incidence of disease recurrence after transplanta-
tion. The reported RI after BM-RIC in patients with
hematologic malignancies is up to 50%.9 In our study, the
relapse incidence in the PTCY group is lower than in pre-
vious reports. One possible explanation may be the fact
that, in our study, patients were transplanted in CR1 or
CR2 while in most previous reports, Haplo-SCT was
mainly used as salvage treatment for advanced stage.
Furthermore, we analyzed a homogenous series of
patients with AML transplanted in CR, and including
both RIC and MAC. In the latter setting, Bacigalupo et
al.19 reported 148 patients receiving PTCY Haplo-SCT,
with an RI for patients in CR1 and CR2 of 11% and 26%,
respectively. 
Our study is the first to analyze the GRFS22 in the setting
PT-CY versus ATG in haplo-SCT
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Figure 2. (A) Acute graft-versus-host disease (aGvHD) grade III-IV, (B) chronic graft-versus-host disease (cGvHD), (C) non-relapse mortality (NRM), and (D) relapse
incidence (RI) for post-transplant high-dose cyclophosphamide (PTCY)-based and anti-thymocyte globulin (ATG)-based GvHD prophylaxis.
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of Haplo-SCT. This end point has been already reported in
the related and unrelated donor settings, and may reflect a
better health status post transplantation and better quality
of life. In our study, the different GvHD prophylaxis pro-
tocols had an impact on GRFS, with better results for the
PTCY-based regimen, in the multivariate analysis. Longer
Haplo-SCT follow up is needed to analyze the impact of
this type of donor on long-term outcomes and complica-
tions. 
Importantly, the center experience, in terms of number
of Haplo-SCT performed per year, was another factor
associated with NRM and GRFS. The center effect was
also demonstrated by our group in the TCD setting both
in children33 and adults.34 This effect may be due to the
different management of post-transplant complications,
life-threatening infections and relapse in each center. Until
now, there has been no standard-of-care in the haploiden-
tical setting, and the management of complications may
vary significantly among different centers. 
Our study has some limitations, being retrospective and
encompassing a variety of conditioning regimens and
GvHD prophylaxis; in addition, registry data on disease
risk features  are not complete. 
One may argue for a potential period effect in transplant
outcomes, with more Haplo-SCT using PT-CY being per-
formed in more recent years. In our series, we reported
patients transplanted between 2007 and 2014.
Importantly, the major changes that lead to about 50%
reduction in transplant-related mortality occurred before
early 2000, as shown by Gooley et al.,35 and there was no
substantial change in transplant procedures and support-
ive care  in this time period.
However, given  the current unavailability of a prospec-
tive randomized trial, our registry-based survey allows
consistent results in a large number of patients. In conclu-
sion, for patients with AML in CR, non-TCD Haplo-SCT
using PTCY with no ATG as GvHD prophylaxis allowed
better LFS and GRFS, lower GvHD and lower NRM than
ATG-based platforms, both using BM and PBSC and in the
RIC and MAC setting. Further prospective randomized
studies are warranted to support our conclusions.
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